Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 1/20 | 0.35 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 10/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530391 | 0.87 | PNMT (0.36) | PNMTF10HTR6ADRA2AADRA2B | |
| SCHEMBL7528283 | 0.85 | PNMT (0.40) | PNMTF10HTR6ADRA2AADRA2B | |
| SCHEMBL3053106 | 0.84 | PNMT (0.50) | PNMTTPSAB1TPSD1TPSG1PARP1 | |
| SCHEMBL4058720 | 0.81 | PNMT (0.46) | PNMTF10HTR6ADRA2AADRA2B | |
| SCHEMBL7531928 | 0.69 | PNMT (0.44) | PNMTTPSAB1TPSD1TPSG1PARP1 | |
| SCHEMBL15071934 | 0.66 | PNMT (0.54) | PNMTF10TPSAB1TPSD1TPSG1 | |
| SCHEMBL7527801 | 0.66 | PNMT (0.51) | PNMTTPSAB1TPSD1TPSG1PARP1 | |
| Hydrochloric Acid SCHEMBL14141606 | 0.65 | PNMT (0.52) | PNMTF10TPSAB1TPSD1TPSG1 | |
| Aziridine SCHEMBL5185484 | 0.65 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP2D6LMNAKDM4E | |
| SCHEMBL4397849 | 0.64 | PNMT (0.61) | PNMTTPSAB1TPSD1TPSG1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169265-B2 | Process for preparing pharmaceutical compounds and intermediate compounds | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-10-27 | — | — | US | disclosed |
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-01-31 | — | — | US | disclosed |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2012-12-27 | — | — | US | disclosed |
| EP-2516447-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077174-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | EGIS GYÓGYSZERGYÁR NYILÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2011-06-30 | — | — | WO | disclosed |
| EP-0785205-B1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-5874581-A | CHEMICAL INTERMEDIATE OF AN ANTIPLATELET MEDICINE AND AN ELASTASE INHIBITOR; REACTING A HALOSILANE AND A 2-OXO-4,5,6,7 -TETRAHYDROTHIENO(3,2-C)PYRIDINE IN THE PRESENCE OF A TERTIARY AMINE | UBE INDUSTRIES, LTD. (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0785205-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030183-A1 | PROCESS FOR PREPARING A PHARMACEUTICAL COMPOUND | CYP3A5, CYP2C19, CYP4B1 | F10 159/4885PARP1 81/4885PARP2 300/4885 |
| US-20120330018-A1 | PROCESS FOR PREPARING PHARMACEUTICAL COMPOUNDS AND INTERMEDIATE COMPOUNDS | CYP3A5, CYP4B1, P2RY6 | F10 642/4885PARP1 489/4885PARP2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.